![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBlQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--8b33408385d3a50b5ea4c08693dfe63a6d0c8c54/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Calixa.png)
Calixa Therapeutics
Calixa is developing hospital-based antibiotics to treat infections resulting from resistant strains of bacteria.
Partner
Brent AhrensInvestment
Series A
Calixa is developing hospital-based antibiotics to treat infections resulting from resistant strains of bacteria.
Series A